Posters

Management of pellucid marginal corneal degeneration with full ring intracorneal implantation

Poster Details

First Author: S. Mojalad Nobari SPAIN

Co Author(s):    C. Villena   K. Jadidi                 

Abstract Details

Purpose:

To evaluate visual and refractive changes in corneas with pellucid marginal degeneration implanted with a full-ring intracorneal implantation (MyoRing, Dioptex, GmbH).

Setting:

Bina Eye Hospital, Tehran, Iran.

Methods:

In this retrospective study, 15 eyes of 15 patients with pellucid marginal degeneration had implantation of MyoRing by means of mechanical dissection using the PocketMaker microkeratome. Surgery was indicated in all cases because of reduced best correction visual acuity (BSCVA) and or contact lens intolerance or dissatisfaction. Preoperative and postoperative evaluations included slit lamp examination uncorrected (UCVA) and best corrected (BCVA) visual acuities, manifest refraction, spherical equivalent (SE) and keratometric readings. A subjective 6- point Likert scale was used to measure overall satisfaction and visual symptoms postoperatively.

Results:

The mean follow up period was 10 months (range 6 to 12 months). The mean UCVA (log MAR) improved significantly from 1.13 ± 0.21 preoperatively to 0.24 ± 0.13 postoperatively (p< 0.001). Preoperative BCVA (log MAR) was 0.39 ± 0.12, postoperatively this improved to 0.19 ± 0.09 (p< 0.001). The mean SE reduced significantly from -6.00 ± 3.60 D to -0.70 ± 1.90 D at the end of the follow-up. The mean cylindrical refraction reduced by 4.00 D postoperatively (p< 0.001). K max decreased by 5.00 D (p< 0.001). The level of satisfaction was very high in 7 patients (46.7%), high in 5 patients (33.3%), moderate in 2 patients (13.3%) and low in one (6.7%) of them.

Conclusions:

MyoRing implantation using PocketMaker microkeratome was a safe and effective procedure for the management of pellucid marginal degeneration and improving the visual problems in these patients. The corneal steepening and astigmatism were reduced in all subjects after MyoRing implantation.

Financial Disclosure:

NONE